Research & Literature

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Satoh M, Tanaka S, Ceribelli A, et al.

Clinical reviews in allergy & immunology 2017; (52(1)):1-19 doi:10.1007/s12016-015-8510-y.

Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.

Ruperto N, Pistorio A, Oliveira S, et al.

Lancet (London, England) 2016; (387(10019)):671-678 doi:10.1016/S0140-6736(15)01021-1.

How Often are Pediatric Patients with Clinically Amyopathic Dermatomyositis Truly Amyopathic?

Oberle EJ, Bayer ML, Chiu YE, Co DO

Pediatric dermatology 2017; (34(1)):50-57 doi:10.1111/pde.13013.

The family impact of caring for a child with juvenile dermatomyositis.

Kountz-Edwards S, Aoki C, Gannon C, et al.

Chronic illness 2017; (13(4)):262-274 doi:10.1177/1742395317690034.

[Clinical and laboratory features of macrophage activation syndrome].

Guo L, Lu MP, Dong GJ, et al.

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2017; (19(2)):188-192.

Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Zhang Y, Milojevic D

Paediatric drugs 2017; (19(3)):193-211 doi:10.1007/s40272-017-0219-3.

Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement.

Berntsen KS, Tollisen A, Schwartz T, et al.

The Journal of rheumatology 2017; (44(6)):827-834 doi:10.3899/jrheum.160997.

Cardiac findings in children with juvenile Dermatomyositis at disease presentation.

Cantez S, Gross GJ, MacLusky I, Feldman BM

Pediatric rheumatology online journal 2017; (15(1)):54 doi:10.1186/s12969-017-0182-0.

Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.

McCann LJ, Pilkington CA, Huber AM, et al.

Annals of the rheumatic diseases 2018; (77(2)):241-250 doi:10.1136/annrheumdis-2017-212141.

Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.

Aouizerate J, De Antonio M, Bader-Meunier B, et al.

Rheumatology (Oxford, England) 2018; (57(5)):873-879 doi:10.1093/rheumatology/kex516.

Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis.

Sahinoz M, Khairi S, Cuttitta A, et al.

Clinical diabetes and endocrinology 2018; (4()):6 doi:10.1186/s40842-018-0058-3.

Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis.

Rosina S, Varnier GC, Mazzoni M, et al.

Current rheumatology reports 2018; (20(5)):29 doi:10.1007/s11926-018-0734-4.

Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.

Soponkanaporn S, Deakin CT, Schutz PW, et al.

Neuropathology and applied neurobiology 2019; (45(4)):410-420 doi:10.1111/nan.12498.

Medications received by patients with juvenile dermatomyositis.

Kishi T, Bayat N, Ward MM, et al.

Seminars in arthritis and rheumatism 2018; (48(3)):513-522 doi:10.1016/j.semarthrit.2018.03.016.

Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria.

Hinze CH, Oommen PT, Dressler F, et al.

Pediatric rheumatology online journal 2018; (16(1)):40 doi:10.1186/s12969-018-0257-6.

Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium to Longstanding Juvenile Dermatomyositis.

Barth Z, Schwartz T, Flatø B, et al.

Arthritis care & research 2019; (71(4)):492-497 doi:10.1002/acr.23687.

Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.

Mamyrova G, Kishi T, Targoff IN, et al.

Rheumatology (Oxford, England) 2018; (57(11)):1956-1963 doi:10.1093/rheumatology/key190.

Juvenile Idiopathic Inflammatory Myopathies.

Huber AM

Pediatric clinics of North America 2018; (65(4)):739-756 doi:10.1016/j.pcl.2018.04.006.

Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis.

Sakurai N, Hino-Shishikura A, Nozawa T, et al.

Modern rheumatology 2019; (29(5)):808-813 doi:10.1080/14397595.2018.1511026.

Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.

Iwata N, Nakaseko H, Kohagura T, et al.

Modern rheumatology 2019; (29(5)):802-807 doi:10.1080/14397595.2018.1511025.

Update on the clinical management of juvenile dermatomyositis.

Huber AM

Expert review of clinical immunology 2018; (14(12)):1021-1028 doi:10.1080/1744666X.2018.1535901.

The Vasculopathy of Juvenile Dermatomyositis.

Papadopoulou C, McCann LJ

Frontiers in pediatrics 2018; (6()):284 doi:10.3389/fped.2018.00284.

Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features.

Yasin SA, Schutz PW, Deakin CT, et al.

Neuropathology and applied neurobiology 2019; (45(5)):495-512 doi:10.1111/nan.12528.

Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts.

Zhong L, Yu Z, Song H

Clinical immunology (Orlando, Fla.) 2019; (198()):11-18 doi:10.1016/j.clim.2018.11.008.

Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.

Wienke J, Deakin CT, Wedderburn LR, et al.

Frontiers in immunology 2018; (9()):2951 doi:10.3389/fimmu.2018.02951.

Juvenile idiopathic inflammatory myopathies: A clinicopathological study with emphasis on muscle histology.

Challa S, Hui M, Jakati S, et al.

Indian journal of pathology & microbiology 2019; (62(1)):61-66 doi:10.4103/IJPM.IJPM_387_17.

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.

Sabbagh S, Pinal-Fernandez I, Kishi T, et al.

Annals of the rheumatic diseases 2019; (78(7)):988-995 doi:10.1136/annrheumdis-2018-215004.

[Juvenile dermatomyositis-what's new?]

Hinze C

Zeitschrift fur Rheumatologie 2019; (78(7)):627-635 doi:10.1007/s00393-019-0643-6.

The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.

Giancane G, Lavarello C, Pistorio A, et al.

Pediatric rheumatology online journal 2019; (17(1)):24 doi:10.1186/s12969-019-0326-5.

Multispecialty approach for improving outcomes in juvenile dermatomyositis.

Wakiguchi H

Journal of multidisciplinary healthcare 2019; (12()):387-394 doi:10.2147/JMDH.S171095.

Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature.

Traineau H, Aggarwal R, Monfort JB, et al.

Journal of the American Academy of Dermatology 2020; (82(2)):317-325 doi:10.1016/j.jaad.2019.07.006.

Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling.

Melki I, Devilliers H, Gitiaux C, et al.

Rheumatology (Oxford, England) 2020; (59(8)):1927-1937 doi:10.1093/rheumatology/kez525.

[Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].

Hou J, Zhou ZX, Li JG, et al.

Zhonghua er ke za zhi = Chinese journal of pediatrics 2019; (57(12)):928-933 doi:10.3760/cma.j.issn.0578-1310.2019.12.007.

Severe Abdominal Manifestations in Juvenile Dermatomyositis.

Besnard C, Gitiaux C, Girard M, et al.

Journal of pediatric gastroenterology and nutrition 2020; (70(2)):247-251 doi:10.1097/MPG.0000000000002575.

Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study.

Liu K, Tomlinson G, Reed AM, et al.

The Journal of rheumatology 2021; (48(1)):114-122 doi:10.3899/jrheum.190494.

Relapsing retroperitoenal abscess secondary to juvenile dermatomyositis: Complexity in management.

Jothinathan M, Lau KS, Vanusha D

The Medical journal of Malaysia 2020; (75(2)):178-180.

Juvenile dermatomyositis presenting as complete heart block in a 10-year-old girl.

Ghosh R, Roy D, Dubey S, et al.

Paediatrics and international child health 2020; (40(4)):251-254 doi:10.1080/20469047.2020.1765123.

Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.

Nguyen M, Do V, Yell PC, et al.

Acta neuropathologica communications 2020; (8(1)):125 doi:10.1186/s40478-020-01007-3.

Echocardiographic study of juvenile dermatomyositis patients: new insights from speckle-tracking-derived strain.

Diniz MFR, Kozu KT, Elias AM, et al.

Clinical rheumatology 2021; (40(4)):1497-1505 doi:10.1007/s10067-020-05418-4.

[The analysis of clinical phenotypes and autoantibodies in juvenile dermatomyositis].

Li DM, Wang L, Liu MY, et al.

Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; (58(12)):966-972 doi:10.3760/cma.j.cn112140-20200724-00751.

Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients.

Sag E, Demir S, Bilginer Y, et al.

Clinical and experimental rheumatology 2021; (39(3)):688-694 doi:10.55563/clinexprheumatol/4tz6ci.

Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis.

Wang A, Morgan GA, Paller AS, Pachman LM

Journal of the American Academy of Dermatology 2021; (84(6)):1610-1618 doi:10.1016/j.jaad.2020.12.032.

Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature.

Xu Y, Ma X, Zhou Z, et al.

Pediatric rheumatology online journal 2021; (19(1)):2 doi:10.1186/s12969-020-00486-x.

Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.

Wang X, Ding Y, Zhou Z, et al.

Pediatric rheumatology online journal 2021; (19(1)):6 doi:10.1186/s12969-020-00492-z.

Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.

Yamasaki Y, Kobayashi N, Akioka S, et al.

Rheumatology (Oxford, England) 2021; (60(10)):4821-4831 doi:10.1093/rheumatology/keab108.

Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.

Leung AKC, Lam JM, Alobaida S, et al.

Current pediatric reviews 2021; (17(4)):273-287 doi:10.2174/1573396317666210426105045.

Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study.

Marstein HS, Godang K, Flatø B, et al.

Pediatric rheumatology online journal 2021; (19(1)):56 doi:10.1186/s12969-021-00543-z.

Incidence, severity and clinical manifestations of juvenile dermatomyositis among Maori and Pacific Island compared to European children.

Concannon A, Han DY

Journal of paediatrics and child health 2021; (57(12)):1881-1885 doi:10.1111/jpc.15595.

Identification of 4 subgroups in juvenile dermatomyositis by principal component analysis-based cluster analysis.

Zhang J, Xue Y, Liu X, et al.

Clinical and experimental rheumatology 2022; (40(2)):443-449 doi:10.55563/clinexprheumatol/t2hxjd.

Mapping the current psychology provision for children and young people with juvenile dermatomyositis.

Livermore P, Gibson F, Mulligan K, et al.

Rheumatology advances in practice 2021; (5(3)):rkab062 doi:10.1093/rap/rkab062.

Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.

He L

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2021; (23(10)):1064-1068 doi:10.7499/j.issn.1008-8830.2106011.

Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: a case report with literature review.

Xia J, Jiang G, Jin T, et al.

BMC pediatrics 2021; (21(1)):488 doi:10.1186/s12887-021-02958-9.

Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis.

Goswami RP, Haldar SN, Chatterjee M, et al.

Autoimmunity reviews 2022; (21(2)):102997 doi:10.1016/j.autrev.2021.102997.

Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis.

Deakin CT, Bowes J, Rider LG, et al.

Human molecular genetics 2022; (31(14)):2471-2481 doi:10.1093/hmg/ddac019.

Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series.

Toplak N, Pimpale Chavan P, Rosina S, et al.

Frontiers in pediatrics 2021; (9()):810785 doi:10.3389/fped.2021.810785.

Anti-nuclear matrix protein 2+ juvenile dermatomyositis with severe skin ulcer and infection: A case report and literature review.

Wang YT, Zhang Y, Tang T, et al.

World journal of clinical cases 2022; (10(11)):3579-3586 doi:10.12998/wjcc.v10.i11.3579.

Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry.

Neely J, Ardalan K, Huber A, et al.

Pediatric rheumatology online journal 2022; (20(1)):50 doi:10.1186/s12969-022-00709-3.

Early Abnormal Nailfold Capillary Changes Are Predictive of Calcinosis Development in Juvenile Dermatomyositis.

Nozawa T, Bell-Peter A, Marcuz JA, et al.

The Journal of rheumatology 2022; (49(11)):1250-1255 doi:10.3899/jrheum.220249.

Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies.

Varnier GC, Consolaro A, Cheng IL, et al.

Rheumatology (Oxford, England) 2023; (62(SI2)):SI163-SI169 doi:10.1093/rheumatology/keac404.

An Unusual Cause of Necrotising Fasciitis in a Young Male with Juvenile Dermatomyositis.

Asante AA, Nsaful J, Dey D

Case reports in rheumatology 2022; (2022()):8758263 doi:10.1155/2022/8758263.

Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.

Sherman MA, Kim H, Banschbach K, et al.

Pediatric rheumatology online journal 2023; (21(1)):3 doi:10.1186/s12969-022-00785-5.

Characteristics of patients with juvenile dermatomyositis from 2001-2021 at a tertiary care center.

Simmons E, Kazmi M, Wilson M, et al.

Dermatology online journal 2022; (28(6)) doi:10.5070/D328659719.

Development of a computed tomography calcium scoring technique for assessing calcinosis distribution, pattern and burden in dermatomyositis.

Cervantes BA, Gowda P, Rider LG, et al.

Rheumatology (Oxford, England) 2024; (63(1)):58-63 doi:10.1093/rheumatology/kead256.

Lung involvement in juvenile idiopathic inflammatory myopathy: A systematic review.

Abu-Rumeileh S, Marrani E, Maniscalco V, et al.

Autoimmunity reviews 2023; (22(10)):103416 doi:10.1016/j.autrev.2023.103416.

Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature.

Chang Y, Shan X, Ge Y

Pediatric rheumatology online journal 2023; (21(1)):106 doi:10.1186/s12969-023-00893-w.

Idiopathic Inflammatory Myopathies.

Balan S, Madan S

Indian journal of pediatrics 2024; (91(10)):1041-1048 doi:10.1007/s12098-023-04896-z.

Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.

Sherman MA, Yang Q, Gutierrez-Alamillo L, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2024; (76(4)):631-637 doi:10.1002/art.42768.

[Advances in the diagnostics and treatment of juvenile dermatomyositis].

Georgi I, Georgi M, Haas JP

Zeitschrift fur Rheumatologie 2024; (83(1)):41-51 doi:10.1007/s00393-023-01454-y.

Successful Treatment of Rapidly Progressive Interstitial Lung Disease in Juvenile Dermatomyositis.

Ciaglia K, Ghawji M, Caraballo M, Sloan E

Pediatrics 2024; (153(3)) doi:10.1542/peds.2023-063268.

Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.

Huang S, Liu Y, Yan W, et al.

Pediatric rheumatology online journal 2024; (22(1)):58 doi:10.1186/s12969-024-00991-3.

Cardiac evaluation of patients with juvenile dermatomyositis.

Akgün G, Sözeri B, Başar EZ, et al.

Pediatric research 2025; (97(1)):333-340 doi:10.1038/s41390-024-03336-8.

Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis.

Tarvin SE, Sherman MA, Kim H, et al.

Arthritis care & research 2024; (76(11)):1532-1539 doi:10.1002/acr.25393.

Profile of patients with Juvenile Dermatomyositis and Anti-MDA5 autoantibodies.

Vignesh P, Nadig PL, Basu S, et al.

Pediatric research 2025; (97(6)):2020-2028 doi:10.1038/s41390-024-03551-3.

Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review.

Kobayashi I

Children (Basel, Switzerland) 2024; (11(9)) doi:10.3390/children11091046.

Rare skin manifestation of juvenile dermatomyositis: peri-orbital oedema and facial swelling.

Polat MC, Altaş MH, Öden Akman A, et al.

Paediatrics and international child health 2024; (44(3-4)):141-145 doi:10.1080/20469047.2024.2406735.

Incidence and outcomes for children with idiopathic inflammatory myopathy in Western Australia-a long-term population-based study.

Nossent J, Keen H, Preen DB, Inderjeeth CA

International journal of rheumatic diseases 2024; (27(10)):e15379 doi:10.1111/1756-185X.15379.

Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies.

Kim H

Paediatric drugs 2025; (27(1)):57-72 doi:10.1007/s40272-024-00658-2.

Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.

Sherman MA, Nicolai R, Datyner EK, et al.

Rheumatology (Oxford, England) 2025; (64(8)):4732-4737 doi:10.1093/rheumatology/keaf086.

Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.

Ravelli A, Rosina S, MacMahon JM, et al.

Annals of the rheumatic diseases 2025; (84(7)):1055-1067 doi:10.1016/j.ard.2025.04.024.

Long-term outcome of juvenile dermatomyositis associated with lipodystrophy: experience of a University hospital.

Kapetanović I, Gajić-Veljić M, Bonači-Nikolić B, Nikolić M

Anais brasileiros de dermatologia 2025; (100(4)):501130 doi:10.1016/j.abd.2025.501130.

Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis.

Yi BY, Wahezi DM, Covert L, et al.

Clinical and experimental rheumatology 2026; (44(2)):390-397 doi:10.55563/clinexprheumatol/35pbbq.

Promising Treatments in Juvenile Dermatomyositis.

Yi BY, Joyce M, Gilbert R, Kim S

Rheumatic diseases clinics of North America 2025; (51(4)):719-735 doi:10.1016/j.rdc.2025.07.012.

Clinical use of intravenous immunoglobulin in juvenile dermatomyositis: indications, treatment course, and clinical outcomes.

Arık SD, Doğru Kılınç A, Menentoğlu B, et al.

Expert opinion on biological therapy 2025; (25(12)):1343-1351 doi:10.1080/14712598.2025.2604058.

Spectrum of clinical phenotypes associated with myositis-specific and myositis-associated antibodies in juvenile idiopathic inflammatory myositis: Our experience from North India.

Vignesh P, Basu S, Nadig PL, et al.

Seminars in arthritis and rheumatism 2026; (78()):152972 doi:10.1016/j.semarthrit.2026.152972.

Use of the EOS 2D/3D Imaging System for the Evaluation of Calcinosis in Juvenile Dermatomyositis: A Retrospective Case Series.

Maguire CA, Lawrence CN, Lala SV, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2026; doi:10.1097/RHU.0000000000002342.

Impact of Juvenile Dermatomyositis on Growth, Puberty, Bone Mineral Density, and Body Composition in Children.

Sudhera N, Kaur H, Pandiarajan V, Singh S

Mediterranean journal of rheumatology 2026; (37(1)):136-145 doi:10.31138/mjr.280725.ran.

Update on clinimetric assessments in juvenile dermatomyositis: conceptual foundations, current tools, and future directions : (Narrative review describing the development, validation, and application of clinimetric outcome measures in juvenile dermatomyositis).

Papadopoulou C, Feldman BM

Pediatric rheumatology online journal 2026; (24(1)).

A multicentre study for clinical phenotype prediction in juvenile dermatomyositis: categorical principal component analysis-based hierarchical clustering.

Torun R, Cüceoğlu MK, Arslanoğlu Aydın E, et al.

Reumatologia 2026; (64(2)):83-93 doi:10.5114/reum/209913.